Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


India Proposes New Body With GM-Based Drug Authority

This article was originally published in PharmAsia News

Executive Summary

India's National Biotechnology Regulatory Authority now in the planning stage may be given responsibility for genetically modified drugs, taking them away from the Drug Controller General of India. The DCGI has responsibility for recombinant biologics, DNA vaccines and other GM drugs from the clinical stage to the market. Draft legislation, however, would transfer that purview to the proposed NBRA, whose role would be confined to drugs such as live vaccines containing organisms, but not human insulin or recombinant vaccines derived from, but not containing GMOs. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts